Evidence map›Paper›PMID 39674321›Full record

ReviewThe Journal of biological chemistry2025

Epitope mapping via in vitro deep mutational scanning methods and its applications.

Meredith M Keen, Alasdair D Keith, Eric A Ortlund

Abstract readReview
In one paragraph

Review in The Journal of biological chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Improving B-cell epitope prediction.Drug discovery today · 2025
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Meredith M KeenDepartment of Biochemistry, Emory School of Medicine, Emory University, Atlanta, Georgia, USA.
Alasdair D KeithDepartment of Biochemistry, Emory School of Medicine, Emory University, Atlanta, Georgia, USA.
Eric A OrtlundDepartment of Biochemistry, Emory School of Medicine, Emory University, Atlanta, Georgia, USA. Electronic address: eortlun@emory.edu.

Funding

Technology Training and Dissemination CoreU54EB027690 · NIBIB · EMORY UNIVERSITY · PI Wilbur A Lam · 2018 to 2026
$96.1M
NIBIB NIH HHS U54 EB027690
6 · The paper itself

Abstract

Epitope mapping is a technique employed to define the region of an antigen that elicits an immune response, providing crucial insight into the structural architecture of the antigen as well as epitope-paratope interactions. With this breadth of knowledge, immunotherapies, diagnostics, and vaccines are being developed with a rational and data-supported design. Traditional epitope mapping methods are laborious, time-intensive, and often lack the ability to screen proteins in a high-throughput manner or provide high resolution. Deep mutational scanning (DMS), however, is revolutionizing the field as it can screen all possible single amino acid mutations and provide an efficient and high-throughput way to infer the structures of both linear and three-dimensional epitopes with high resolution. Currently, more than 50 publications take this approach to efficiently identify enhancing or escaping mutations, with many then employing this information to rapidly develop broadly neutralizing antibodies, T-cell immunotherapies, vaccine platforms, or diagnostics. We provide a comprehensive review of the approaches to accomplish epitope mapping while also providing a summation of the development of DMS technology and its impactful applications.

Indexed as

Epitope MappingEpitopesMutationAnimalsHumansEpitopesantibody engineeringdeep mutational scanningdiagnosticsepitope mappingimmunotherapieslinking genotype to phenotypevaccine designviral surveillance

Identifiers

PMID39674321
PMCPMC11783119

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.